Quarterly report pursuant to Section 13 or 15(d)

Accrued Liabilities and other Long-Term Liabilities (Schedule of Accrued Expenses and Other Long-Term Liabilities) (Details)

v3.21.1
Accrued Liabilities and other Long-Term Liabilities (Schedule of Accrued Expenses and Other Long-Term Liabilities) (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Accrued expenses:    
Professional fees $ 1,592 $ 1,236
Salaries, bonus and related benefits 5,983 6,701
Research and development 4,234 5,007
Research and development - manufacturing 0 518
Research and development - license maintenance fees 564 461
Research and development - milestones 600 600
Accrued royalties payable 2,048 2,682
Accrued coupon expense 10,944 10,869
Other 1,846 1,188
Total accrued expenses 27,811 29,262
Other long-term liabilities:    
Deferred rent and long-term lease abandonment charge 1,903 1,949
Partner company note payable, long-term 5,613 7,359
Total other long-term liabilities and partner company note payable, long-term 7,516 9,308
Ximino [Member]    
Other long-term liabilities:    
Total other long-term liabilities and partner company note payable, long-term 3,790 3,622
Oral Acne Product (Isotretinoin) [Member]    
Other long-term liabilities:    
Total other long-term liabilities and partner company note payable, long-term 1,823 2,792
Anti-itch Product [Member]    
Other long-term liabilities:    
Total other long-term liabilities and partner company note payable, long-term $ 0 $ 945